Close Menu

NEW YORK – Fulgent Genetics and BioIQ announced Tuesday a partnership to identify variants of SARS-CoV-2, the virus that causes COVID-19, using next-generation sequencing.

BioIQ, an Atlanta-based diagnostic testing software company, will offer Fulgent's coronavirus genome sequencing assay on its software platform to its employer, government, and health plan customers to inform testing regimens, clinical treatment protocols, and vaccination strategies.

Financial and other terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Mar
18
Sponsored by
Thermo Fisher Scientific

Viruses mutate as they strive to thrive in response to selective pressures.

Mar
29
Sponsored by
Thermo Fisher Scientific

Global genetic surveillance is vital for understanding the evolution of viral pathogens and monitoring for changes in transmissibility, virulence, disease pathology, and impact on the efficacy of diagnostic tests, therapeutics, and vaccines.

Apr
06
Sponsored by
Beckman Coulter

In this webinar session, Dr. David Harris and Dr. Ryan Sprissler, who led the student and employee testing program at University of Arizona, will discuss how the university has remained physically open with nearly 25 percent of its population on campus, while keeping infection rates below 2 percent.